Clinical Trials Browser

Phase 4 × Tumor Lysis Syndrome × Other hematologic neoplasm × Clear all

NCT04745910 2025-12-18

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

Phase 4 Active not recruiting

Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

NCT00230217 2009-03-30

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Phase 4 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Neoplasms, Recurrence, Tumor Lysis Syndrome, Hyperuricemia